Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCA1NX)

• Drug Name: MK-4280 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Neoplasm	2A00-2F9Z	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMCA1NX

Molecule-Related Drug Atlas

Drug(s) Targeting Lymphocyte activation gene 3 protein (LAG3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Relatlimab	DM28AZV	Melanoma	2C30	Approved	[4]
Anti-LAG3	DMJO402	Gastric adenocarcinoma	2B72	Phase 2	[5]
BMS-986016	DMDCHM7	Hematologic tumour	2B33.Y	Phase 1/2	[6]
IMP-321	DM18ZLW	Allergy	4A80-4A85	Phase 1/2	[7]
Favezelimab	DMYAIE2	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[8]
XmAb22841	DMQB3HD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
FS118	DM0QH9K	Advanced cancer	2A00-2F9Z	Phase 1	[10]
RG6139	DMJFM3O	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
ADPT01	DMS6DPF	Breast cancer	2C60-2C65	Phase 1	[12]
IMP-701	DMXSMF9	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lymphocyte activation gene 3 protein (LAG3)	TTNVXAW	LAG3_HUMAN	Inhibitor	[3]

References

• [1] ClinicalTrials.gov (NCT02720068) Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction. J Immunol Methods. 2018 May;456:7-14.
• [4] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761234
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 March; 7(2): 85-96.
• [7] A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol. 2007 Sep 15;179(6):4202-11.
• [8] A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 2022 Dec;7(6):100639.
• [9] Clinical pipeline report, company report or official report of Xencor.
• [10] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [11] Clinical pipeline report, company report or official report of Genentech.
• [12] Clinical pipeline report, company report or official report of Novartis.
• [13] IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5.